Stock-Based Compensation for Edwards Lifesciences (EW)
Stock-Based Compensation for Edwards Lifesciences (EW): headline value $158.10M · YoY -2.6%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
Currently viewingStock-Based CompensationSwitch metric
Latest period
$158.10M
YoY change
-2.6%
5Y CAGR
+11.3%
Peak year (2024)
$162.30M
Latest annual
$158.10M
Stock-Based Compensation history chart for Edwards Lifesciences (EW) from 1999 to 2025
Stock-Based Compensation history table for Edwards Lifesciences (EW) from 1999 to 2025
| Fiscal year | Period ended | Reported | Stock-Based Compensation | YoY |
|---|---|---|---|---|
| 2025 | $158.10M | -2.6% | ||
| 2024 | $162.30M | +16.4% | ||
| 2023 | $139.40M | +9.9% | ||
| 2022 | $126.80M | +16.0% | ||
| 2021 | $109.30M | +18.0% | ||
| 2020 | $92.60M | +13.9% | ||
| 2019 | $81.30M | +14.5% | ||
| 2018 | $71.00M | +15.3% | ||
| 2017 | $61.60M | +8.3% | ||
| 2016 | $56.90M | +14.0% | ||
| 2015 | $49.90M | +3.3% | ||
| 2014 | $48.30M | +1.9% | ||
| 2013 | $47.40M | +12.6% | ||
| 2012 | $42.10M | +20.3% | ||
| 2011 | $35.00M | +19.5% | ||
| 2010 | $29.30M | +3.5% | ||
| 2009 | $28.30M | -1.4% | ||
| 2008 | $28.70M | +3.6% | ||
| 2007 | $27.70M | +4.1% | ||
| 2006 | $26.60M | — | ||
| 2005 | $0 | — | ||
| 2004 | $0 | — | ||
| 2003 | $0 | — | ||
| 2002 | $0 | — | ||
| 2001 | $0 | — | ||
| 2000 | $0 | — | ||
| 1999 | $0 | — |
Stock-Based Compensation values are taken from Edwards Lifesciences's reported cash flow statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
The 2025 reading of Edwards Lifesciences (EW) stock-based compensation is $158.10M – edged down 2.6% year-over-year.
Edwards Lifesciences stock-based compensation compound annual growth for the 2020–2025 (5 years) window is +11.3%, with the latest reading among the more recent periods of the dataset.
The highest annual stock-based compensation of $162.30M was reported in 2024. The lowest in the available history was $0 in 1999.
Within Healthcare, Edwards Lifesciences (EW) ranks 5th among 8 peers we track. The peer median for stock-based compensation is $313.00M.
Edwards Lifesciences Stock-Based Compensation by Year
Edwards Lifesciences Stock-Based Compensation 2025: $158.10M
Edwards Lifesciences stock-based compensation in 2025 was $158.10M, edged down 2.6% below 2024.
Edwards Lifesciences Stock-Based Compensation 2024: $162.30M
Edwards Lifesciences stock-based compensation in 2024 was $162.30M, grew 16.4% from 2023. This figure represents the highest annual value in the available history.
Edwards Lifesciences Stock-Based Compensation 2023: $139.40M
Edwards Lifesciences stock-based compensation in 2023 was $139.40M, grew 9.9% from 2022.
Edwards Lifesciences Stock-Based Compensation 2022: $126.80M
Edwards Lifesciences stock-based compensation in 2022 was $126.80M, grew 16.0% from 2021.
Edwards Lifesciences Stock-Based Compensation 2021: $109.30M
Edwards Lifesciences stock-based compensation in 2021 was $109.30M.
See more financial history for Edwards Lifesciences (EW).
Sector peers — Stock-Based Compensation
Companies in the same sector as Edwards Lifesciences, ranked by their latest stock-based compensation.
| Company | Stock-Based Compensation | Sector |
|---|---|---|
| Johnson & Johnson (JNJ) | $1.35B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $971.00M | Healthcare |
| AbbVie Inc. (ABBV) | $955.00M | Healthcare |
| Eli Lilly and Company (LLY) | $626.00M | Healthcare |
| AstraZeneca PLC (AZN) | $0 | Healthcare |
| Merck & Co., Inc. (MRK) | $0 | Healthcare |
| Amgen Inc. (AMGN) | $0 | Healthcare |
| Novo Nordisk A/S (NVO) | $0 | Healthcare |
Frequently asked questions
What is Edwards Lifesciences's stock-based compensation?
Latest reported stock-based compensation for Edwards Lifesciences (EW) is $158.10M (period ending December 31, 2025).
How has Edwards Lifesciences stock-based compensation changed year-over-year?
Edwards Lifesciences (EW) stock-based compensation changed -2.6% year-over-year on the latest annual filing.
What is the long-term growth rate of Edwards Lifesciences stock-based compensation?
Edwards Lifesciences (EW) stock-based compensation compound annual growth rate is +11.3% over the most recent 5 years available.
When did Edwards Lifesciences stock-based compensation hit its highest annual value?
Edwards Lifesciences stock-based compensation reached its highest annual value of $162.30M in 2024.
What was Edwards Lifesciences stock-based compensation in 2024?
Edwards Lifesciences (EW) stock-based compensation in 2024 was $162.30M.
What was Edwards Lifesciences stock-based compensation in 2025?
Edwards Lifesciences (EW) stock-based compensation in 2025 was $158.10M.
Metrics overview
Pick a metric for charts, filings and peers — each row shows the latest TTM or most-recent-quarter value.
Explore more
EW Overview
Company profile, financial tools, and key metrics
EW Revenue Counter
Earns $199.88 every second. See per minute, hour, and day.
EW Earnings Counter
Earns $34.65 per second net profit. See per minute, hour, and day.
EW Economic Scale
Exceeds Fiji's GDP. Compare with world economies.
EW What If Invested
What if you had invested $1,000? See historical returns from any date.
EW How It Makes Money
Discover visual breakdown of $6.30B in revenue — where it comes from and where it goes.
EW Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
EW Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
EW Daily Price Character
Balanced · 50.0% historical win rate (green days). Streaks & record days.
EW Buybacks
0.93% TTM buyback yield. Shareholder yield & SBC comparison.
EW Stock Split History
3 splits on record. Dates, ratios, and cumulative multiple.